Speakers: 

Lily Wood, Pharmacy Intern, Geisinger Community Medical Center - has nothing to disclose. 

Maia Cogley, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Philip Davis, Pharmacy Intern Technician, Geisinger Medical Center - has nothing to disclose. 

Moderator: 

Sarah F. Hale, PharmD., BCPPS; Director of Pharmacy, Geisinger Medical Center - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

•  

• Identify risk factors associated with the development of aneurysm and artery dissection in adults with cancer following the use of oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).

• Recognize the rationale for using capecitabine as an active comparator to oral VEGFR-TKIs in the study design.

• Recognize the impact of ventilator-associated pneumonia on patient care in the intensive care unit.

• Analyze the evidence supporting the use of inhaled amikacin for prevention of ventilator-associated pneumonia and its applicability to treated patient populations.

• Compare the results of the meta-analysis to previous literature and current Geisinger policy.

• Devise a seizure prophylaxis plan for patients presenting with traumatic brain injuries.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD; Brain Simpkins, PharmD; Jessica Milheim, CPhT and Nichole Varela Gonzalez, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.